Systemic HypertensionSystemic HypertensionСистемные гипертензии2075-082X2542-2189Intermedservice Ltd2895810.26442/SG28958ArticlesСтатьиResearch ArticleSartans in the treatment of high-risk hypertension: the abilities of candesartanСартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартанаMorozovaT EМорозоваТатьяна Евгеньевна

д-р мед. наук, проф., зав. каф. клинической фармакологии и фармакотерапии ФППОВ

temorozova@gmail.comГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ15062013102VOL 10, NO2 (2013)ТОМ 10, №2 (2013)131809042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.eco-vector.com/2075-082X/article/view/28958

This paper presents an overview of the literature on the treatment of arterial hypertension drugs that block the renin-angiotensin-aldosterone system (RAAS) – angiotensin receptor blockers ΙΙ (ARB), whose action is based on inhibition of the RAAS at the AII receptor. ARB candesartan (atakand), along with a strong long-term antihypertensive effect has organoprotective (causes regression of LVH has nephroprotection) antidiabetogennym effect, prevents the development of stroke. Clinical experience suggests candesartan, high efficiency and a good range of security among different categories of hypertensive patients with concomitant pathology, chronic heart failure, diabetes, obesity.

В работе представлен обзор литературы по вопросам лечения артериальной гипертензии препаратами, блокирующими активность ренин-ангиотензин-альдостероновой системы, – блокаторами рецепторов ангиотензина II, действие которых основано на торможении активности ренин-ангиотензин-альдостероновой системы на уровне рецепторов ангиотензина II. Блокатор ангиотензиновых рецепторов кандесартан (Атаканд®) наряду с выраженным долгосрочным антигипертензивным действием обладает органопротективными свойствами (вызывает обратное развитие гипертрофии левого желудочка, оказывает нефропротекцию), антидиабетогенным действием, предупреждает развитие мозгового инсульта. Опыт клинического применения кандесартана свидетельствует о высокой эффективности и хорошем спектре безопасности у разных категорий больных артериальной гипертензией, при сочетанной патологии, при хронической сердечной недостаточности, сахарном диабете, ожирении.

hypertensionhypertensionantihypertensive therapyblockade of the renin-angiotensin-aldosterone systemangiotensin receptor blocker IIorganoprotectiveregression of LVHcandesartanAtakand®артериальная гипертензияантигипертензивная терапияблокада ренин-ангиотензин-альдостероновой системыблокатор рецепторов ангиотензина IIорганопротекциягипертрофия миокарда левого желудочкакандесартанАтаканд®Ezzati M, Lopez A, Rodgers A et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization, 2004.Chobanian A.V. Shattuck Lecture. The hypertension paradox – more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361: 878–87.Диагностика и лечение АГ. Рекомендации Российского медицинского общества по АГ и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика. 2010; 7 (6). Прил. 2.Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462–536.Haralambos P. Gavras, Salernob C.M. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18 (6): 1058–67.Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 18S–24S.Edwards R.M., Aiyar N, Ohlstein E.H. et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175–81.Israili Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73–86.Puig J.G. et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertension 1999; 17: 1033–9.Wurzner C et al. Comparative effects of losartan and ibresartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertension 2001; 19: 1855–60.Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.Granger C.B., Mc Murray J.J.V et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function intolerant to angiotensin - converting - enzyme inhibitors: the CHARM - Alternative trial. Lancet 2003; 362: 772–6.Brenner B.M., Cooper M.E., de Zeeuw D et al. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). N Engl J Med 2001; 345: 861–9.Julius S, Kjeldsen S.E. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE. Lancet 2004; 363: 2022–31.Vauquelin G, Fierens F.L.P, Verheijen I et al. Distinctions between non - peptide angiotensin II AT1 - receptor antagonists. JRAAS 2001; 2 (Suppl. 1): S24–S31.Unger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Pressure 2000; 9 (Suppl. 1): 14–8.Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil possible mechanisms of long - term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.Hubner R, Hogemann A.M., Sunzel M, Riddell J.C. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19–S25.Unger T. Inhibiting renin - angiotensin in the brain: the possible therapeutic implications. Blood Pressure 2001; 10 (Suppl. 1): 12–6.Van Lier J.J., van Heiningen P.N.M, Sunzel M. Absorption, metabolism and excretion of 14C - candesartan and 14C -candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S27–S28.Sever P, Holzgreve H. Long - term efficacy and tolerability of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13 (Suppl. 1): S69–S73.Mc Innes G.T., O'Kane K.P.J, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl. 1): S75–S80.Belcher G, Hubner R, George M et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 13 (Suppl. 1): S85–S89.Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patients group. Blood Pressure 2000; 9 (Suppl. 1): 27–30.Andersson O.K., Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II, in comparison with losartan. Blood Pressure 1998; 7 (1): 53–9.Bakris G.L., Gilles T.D., Weber M.A. Clinical efficacy and safety profiles of AT1-receptor antagonists. Cardiovascul Rev Reports 1999; 20 (2): 1–19.Bakris G, Grandma Reef M et al. Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM study. J Clin Hypertens 1001; 3: 16–21.Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II receptor antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1999; 13 (Suppl. 1): S49–S57.Hennersdorf M.G., Strauer B.E. Arterial hypertension and cardiac arrhythmias. J Hypertens 2001; 19: 167–77.Klingbeil A.U., Schneider M, Martus P et al. A meta - analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–6.Spratt J, Shiels A, Williams B et al. On behalf of the LVH study group. Effects of candesartan cilexetil on left ventricular and arterial structure and function in hypertensive patients. J Hypertens 2000; 18 (Suppl. 2): S188.Cuspidi C, Muiesan M.L., Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.Lindholm L.H., Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatmen and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563–74.Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875–86.Pfeffer M.F., Swedberg K, Granger C.B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: CHARM - overall program. Lancet 2003; 362: 759–66.Yusuf S, Ostergren J.B., Gerstein H.C. et al. Effect of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48–53.Burgess E. Renal effects of angiotensin II receptor antagonists. Blood Pressure 2000; 10 (Suppl. 1): 17–20.Morgensen E, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade renin - angiotensin system in patients with hypertension, microalbuminuria, and non - insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.Андрущишина Т.Б., Морозова Т.Е. Интенсивный контроль артериального давления: возможности комбинированной фармакотерапии. Системные гипертензии. 2009; 2: 22–7.Морозова Т.Е., Юдина И.Ю. Современная стратегия улучшения приверженности лечению больных артериальной гипертонией: фиксированные комбинации лекарственных средств. Cons. Med. 2010; 1: 22–8.